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1. Introduction
1.1. Opioid substitution therapy
Substitution therapy for opiate abusers reduces dependencies on illicit drugs by utilizing
opioid agonists that bind to opioid receptors in the brain. Apart from the physical benefits of
reducing cravings and withdrawal symptoms, it also plays a role in reducing other problems
associated with opioid abuse. Their longer duration of action means they do not require
frequent administration and hence enables patients to carry out activities of daily living
without disruption. The spread of infectious blood borne diseases is also curbed by the fact
that they are usually administered orally [1].
Methadone and buprenorphine are the two most commonly prescribed and effective opioid
agonists for substitution maintenance therapy in Malaysia as their oral preparation can avoid
injecting behaviour among opiate users. Hence, the harm reduction promotion will be further
strengthen as injecting related behaviour among opiate users are the main contributor to HIV
transmission in Malaysia. Methadone Maintenance Therapy (MMT) was started in 2005
through harm reduction programme and is getting a strong foothold since then. Therefore we
are seeing a lot of opioid abuser on methadone in Emergency Department with potential
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overdose or withdrawal symptoms. A lot of these opiate abuser drafted into the program also
frequently have whole hosts of other health problems such HIV, Hepatitis B and C or Tuber‐
culosis which may complicate diagnosis and treatment.
MMT adds importantly to our ability to deal with the ever increasing menace of illicit drug
use. Methadone is a long-acting drug. It occupies the opioid receptors at a slow pace and this
creates a steady level of opioid in the blood. This characteristic avoids the "high and low” levels
that generally occur with short-acting opioid administrations.
1.2. Methadone Pharmacokinetics (PK)
The efficacy of methadone is determined by the stability of methadone concentration in blood,
and therefore in the action site located in the brain. Maximum concentration of methadone is
reached around two to four hours after dose administration and gradually falls until the
moment of next dose administration. As Methadone is extensively metabolized in the liver, its
metabolic clearance is shown by the elimination rate of methadone. The clearance rate of
methadone from the body was found to be 158 ml/ min and 129 ml/ min for (R)-methadone
and (S)-methadone respectively. Main metabolite of methadone, which is 2-ethylidene-1, 5-
dimethyl-3, 3-diphenylpyrrolidine is inactive. The apparent volumes of distribution were
varies with mean values 3.9 l/kg [2]. Methadone is administered single daily as in methadone
maintenance treatment, the average half-life of methadone is around 24 hours. This means that
at the end of the 24th hour after dose administration, the concentration of methadone should
have fallen to half its peak value. Most of us would consider the increasing methadone
concentration in the blood is associated with the increasing dose. However, this general rules
is not necessarily expected as we can see in the patients with methadone doses as high as 70–
170 mg per day, have blood concentrations similar to those of patients whose doses are as low
as 25 mg per day. It is note that the blood concentrations of methadone act as an indicator of
its concentration in the action sites than the dose taken. Because of this, methadone plasma
concentrations measured after 24 hours have repeatedly been proposed as a parameter for the
evaluation of the adequacy of treatment. The necessary level of plasma methadone concen‐
tration is found between 150 and 600 ng/ml to counter for the craving effect of opioid addicts
[3]. However, plasma concentration differs in different individuals and in single person under
different conditions. The determinant factor for this variability include genetic factor, physio‐
logical, pathological, and pharmacological factor. Methadone is metabolized in the body by
the enzymes of P450 cytochrome system . Polymorphism in cytochrome CYP450 can affect a
higher or lower level of its activity and responsible for a more rapid or a slower elimination
of methadone, with a consequent shortening or lengthening of methadone’s half-life and a rise
or fall in its levels in plasma. Concentration of methadone in blood is influenced by various
steps of absorption, plasma protein binding, metabolism and excretion processes. Interference
at the level of the P450 microsomal system also can cause an induction of the methadone
metabolism, with a consequent fall in its levels in plasma, or an inhibition of its metabolism,
with a rise in methadone levels in plasma. Less than 200 ng/ml is associated with poor
compliance and higher than 700 ng/ml is associated with toxicity, ranges from excessive
sedation with small pupils, respiratory depression and fatal tachyarrhythmia such as torsade
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de pointes (TdP) [4]. Based on the methadone concentration in plasma, inter-individual and
intra-individual varieties persist in response to methadone. By studying plasma concentration,
probably the optimum dose of methadone can be achieved faster and minimized unwanted
side effect, therefore the patient will remain in the MMT programme [5]. Other special feature
of methadone is it undergoes extended reversible absorption into tissues particularly the liver
and hence steady-state concentrations can be achieved after multiple administrations. Meth‐
adone is usually administered orally and as such is rapidly absorbed. There are two processes
involved in metabolizing methadone, primarily in the liver namely demethylation and
cyclization. The cyclization process produces 2-Ethylidene-1, 5-dimethyl-3,3-diphenylpyrro‐
lidine (EDDP) distinct from its parent molecule. Methadone and metabolites are primarily
excreted in the feces. Unmetabolized methadone excretion in the urine accounts for less than
11% of the administered dose. It is excreted unchanged and as its metabolite in the urine. The
excretion of methadone is markedly enhanced by the acidification of the urine
1.3. Methadone: AUC
Major measurements in pharmacokinetic study are plasma and urine. Plasma concentration
data provides an important data in PK study. The AUC (the area under curve) can be presented
graphically as the area under the plasma concentration versus time curve. AUC is an important
parameter in PK analysis as it often used to measure the drug exposure. AUC plays many
important roles in pharmacokinetics. AUC provides a measure how much and how long a
drug stays in a body. [6] In other words, AUC shows an overall amount of drug in the
bloodstream after a dose administration. Studying AUC probably is the best way to under‐
stand how people handle a drug. The plasma concentration of the drug measured by AUC can
be useful for clinicians or doctors to optimize the drug dosage. Each person who takes
methadone has differences in the way their body handles the drug in terms of absorption,
distribution, metabolism and/or elimination processes. Therefore, a patient can have a high or
low methadone blood levels after taking the same dose just because of the way they handle
the drug. The PK of drug also changed by certain factors. For example, the blood levels of
methadone can be increased or lowered by not following the food requirements with dosing,
taking antacids with the drugs, or taking certain other drugs or herbals that can cause big
inhibition or induction interactions in drug metabolism. Thus, it is important to find the dose
requirements out so that patients know how best to take the drugs. Finally, the level of drug
concentration in the body affect how well the drug works and whether the drug might cause
side-effects, particularly in a case of high drug levels. Low levels of drug also can result in poor
efficacy of the methadone maintenance treatments. In case of "therapeutic drug monitoring"
(TDM), a doctor may think to measure methadone blood levels as a best idea to adjust the dose.
Based on the results, the doses may be adjusted and then re-check the blood levels of drug to
try and get them right where they want them [7]. Much information can be obtained on drug
absorption, disposition of drug molecules between blood and tissues and drug elimination by
measuring the amounts or the concentrations of drugs in blood, urines or other fluids or tissues
at different times after the administration. AUC is a parameter that is dependent on the drug
amount that enter into the systemic circulation and on the ability that the system has to
eliminate the drug (clearance). Therefore it can be used to measure the drug amount absorbed
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or the efficiency of patient’s physiological processes that characterize the drug elimination.
Accurate estimation of the AUC can be achieved by applying “trapezoidal rule” [8]. AUC can
be calculated by two PK models, which are linear PK models and non-linear PK models. Linear
PK models are conducted without specifying any mathematical models (noncompartmental
methods). It is helpful to use linear models as a guide in therapeutic decision making [9].
1.4. Volume of distribution (Vd)
The amount of drug in the body calculated from measurement of plasma concentration is
assessed using a parameter called Volume of Distribution (Vd). The clinical importance of Vd
is for computing a loading dose (eg. the ﬁrst dose of a multiple dosage regimen) to reach the
target therapeutic plasma concentration [10]. For example, if 1000 mg of a drug is given and
the subsequent plasma concentration is 10 mg/L, that 1000 mg seems to be distributed in 100
L (dose/volume = concentration; 1000 mg/x L = 10 mg/L; therefore, x = 1000 mg/10 mg/L = 100
L). Vd is not the actual volume of the body or it’s fluid compartment, but it is the distribution
of a drug in the body. For the drug that is highly-bounded by a tissue, the dose that remains
in the circulation is low, hence plasma concentration will be low and Vd will be high [11].
Methadone is a lipophilic drug and exhibits tissue distribution [12]. Methadone is also widely
distributed to brain, kidney, gut, liver, muscle and lung with their specific plasma partition
coefficients [13]. Vd of methadone is reported to be high in humans [14]. The apparent volume
of distribution at steady-state (Vss) studied by other authors is much higher than actual
physiological volume, indicating that methadone is predominantly tissue-bounded compared
to plasma proteins binding. In opiate addicts, Vss of methadone ranged from 4.2 – 9.2 l/kg and
in patient with chronic pain, the Vss is from 1.71 – 5.34 l/kg [15]. Methadone is highly bound
to plasma protein by 86% and it is similar as reported in rats [16], [17]. Because of basic
properties of methadone, it binds predominantly to α1-acid glycoprotein (AAG) [18, 19]. AAG
is an acute-phase serum protein that exhibits different concentration in plasma levels based
on physiological or pathological conditions. In stress condition, AAG will increase and this
will result in lower free fraction (fu) of methadone in plasma of cancer patients and opiate
addicts compared in healthy volunteers [20,21]. Hence, after rapid administration of metha‐
done, fu will decrease in early period and total plasma drug concentration (Cp) will increase
as Vss is proportional to fu, but unbound plasma drug concentration (Cu) remains unchanged.
A study on methadone distribution should pay attention on demographics features like weight
and sex and AAG. About 33% Interindividual variability in Vss is due to sex and weight.
Female exhibit higher Vss than male and this is related to weight. Meanwhile, a decrease in
Vss is associated in time-dependent increase in AAG. [22]
1.5. Metabolism of methadone
Methadone is  used clinically  as  a  racemate,  although R-enantiomers  are  responsible  for
the activation of  opioid activity.  The major pathway in methadone metabolism is  N-de‐
methylation  to  inactive  2-ethylidine-1,5-  dimethyl-3,3-diphenylpyrrolidine  (EDDP).  This
activity  is  mediated  by  cytochrome  P450  CYP3A4  and  CYP2B6  and  somewhat  by
CYP2C19 in vitro which was less active [23]. In vitro, CYP2B6 is regarded as a predomi‐
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nant catalyst of stereo-selective methadone metabolism and may be a major determinant
of methadone metabolism and disposition in vivo. In addition, CYP2B6 activity and ster‐
eo-selective  metabolic  interactions  may  confer  variability  in  methadone  disposition.
CYP3A4 is  the  most  abundant  CYP form in  the  liver.  No genetic  polymorphism is  ob‐
served in this enzyme. However,  interindividual variability in the expression of this en‐
zyme  had  been  noted.  CYP3A4  is  inducible  and  this  might  be  the  reason  for  the
induction  of  the  methadone  metabolism  at  the  beginning  of  a  maintenance  treatment.
Thus, a pattern of decrease in steady-state plasma levels of methadone is observed dur‐
ing maintenance treatment with racemic methadone [24]. Meanwhile, CYP2B6 gene is re‐
ported to be highly polymorphic. It is noted that CYP2B6 has a couple of variant alleles
that are associated with lower expression/activity. Among of those alleles are CYP2B6*6,
CYP2B6*16 and CYP2B6*18 in particular [25, 26, 27]. CYP2B6*6 is rather common in sev‐
eral  different  populations (20–30% frequency),  whereas both CYP2B6*16 and CYP2B6*18
are common in Black subjects  where the allele  frequency is  relatively high,  about  7–9%
[26,  27].  To  a  smaller  extent  CYP1A2 enzymes  which  is  found in  the  kidney  may also
has  influence  on  methadone  metabolism.  Knowledge  from genotype  analyses  is  impor‐
tance in clinical use. It is an explanation for us to understand the therapeutic problem or
a failure in question based from three major  population phenotype,  and these are  poor
metabolisers  (PM),  lack of  functional  enzyme due to defective or  deleted genes,  the ex‐
tensive metabolizers  (EM),  carrying 2  functional  genes;  and the ultra-rapid metabolizers
(UM), with more than 2 active genes encoding a certain P450 [27]. This genotyping anal‐
yses definitely will  be a valuable aspect to contribute to a more efficient and safer drug
therapy in the psychiatric clinic possible.
1.6. Dose of methadone
The believe that zero drug is best has similarly also led to frequent premature cessation of
MMT, even though evidence suggests that maintenance therapy for at least two years is
required for the maximum probability of success. Ironically the reason to discontinue MMT
quite often comes from care providers working in maintenance programs. They often do not
try to adequately address the reasons why patient was taking opioid was taken in the first
place or the existence of coexisting psychiatric illnesses. This frequently results in increasing
anxiety among patients that may explain their needs for other mood-altering drugs, such as
the benzodiazepines. A lot of physicians who are directly involved in MMT programs in
Malaysia or indeed worldwide are quite reluctant to increase dose to a required level due to
the lack of understanding of methadone Adverse Drug Reactions (ADR). Although its efficacy
and safety are well documented worldwide throughout the world, the bad perception of opioid
is hard to shake off. A serious side effect like hypoventilation, respiratory depression, ar‐
rhythmia and prolonged QT interval were rare and normally occurs with other concomitant
drugs such as benzodiazepine [28]. Most guidelines advises gradual increase in methadone
dose to achieve sufficient tolerance so that an injection of any amount of street opioid will not
be able to produce euphoria, thus eliminating the reward for injecting drugs. A high dose of
methadone is usually required to achieve this effect and it averages 80 - 100 mg per day.
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Typically when these principles are followed, MMT is effective with a tolerable adverse drug
reaction (ADR), and the individual and society can gains from it.
It  is  however  unfortunate  that  these  principles  are  rarely  followed.  Consequently,  al‐
though current knowledge supports a daily dose of at least 80 mg to 100 mg to abolish
further  craving  for  opioids,  a  big  majority,  including  in  Malaysia,  are  maintained  on
much lower doses [5,  28-31].  To ascertain optimal dosing for MMT in clinical settings is
very  challenging.  As  explained  before,  higher  doses  (>  80mg)  had  been  postulated  to
have serious adverse drug reactions (ADR) while low dose encourage defaulter and illic‐
it  drug seeking behaviour.  It  has  been observed that  physicians are  too afraid to  maxi‐
mize methadone dosage to a  required level  mainly due to misconception about its  side
effects.  This  study hopes to  clarify  this  misconception and encourage physician to  opti‐
mize personalized methadone dosing. In view of the heavy burden of opioids addiction
to  society  generally  and  healthcare  specifically,  we  choose  to  study  about  methadone
substitution therapy and its  implementation in details.  Our focus is  to compare the dif‐
ferent  of  ADR between  high  dose  methadone  and low dose  methadone.  We hope  that
the  results  from our  study  will  be  able  to  highlights  the  main  side  effects  in  different
methadone  groups,  its  safety  profile  and  ultimately  encourage  a  higher  dose  MMT re‐
gime.  An  increasing  importance  of  methadone  as  an  effective  substitution  therapy,  as
well  as  its  potential  in  treating chronic  pain as  in  outpatient  settings warranted further
evaluation of its safety and efficacy [32-34]. Though we are likely producing results that
have already been studied, we feel  it  is  still  important as these have never been shown
in our local setting. Local data such as these is extremely important in trying to convince
the  authorities  in  adopting  new  and  bold  measures  to  combat  the  drug  abuse  menace
and the rise of HIV in Malaysia.
By determining the relationship between clinical dose of methadone and its plasma level, the
methadone prescribers would probably able to determine the relationship between clinical
dose of methadone with its plasma level for a better optimum dose for the best effect and
response. This would further helping physician in determining and evaluate the different
withdrawal effects in opioid dependant subjects with different doses of methadone. The end
point measurement of this would probably keep opioid dependent patients remain in the MMT
programme for a better monitoring and curbing the spread of HIV infection through the
intravenous routes.
2. Methods and material
This was a comparative prospective cross sectional study, in which the sample size will be
selected from MMT clinic run by government institution ( HUSM Psychiatric Department) and
from the authorized private MMT centre (Klinik Sahabat, Kota Bharu).
The patients selected were already enrolled into MMT programme in these clinics. During
recruitment phase, we will ensure that the subjects were already receiving daily methadone
therapy for 6 month, hence minimize early adverse symptoms during induction phase. During
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recruitment phase, baseline ECG from the clinics will be studied. If these pre-induction
baseline ECGs shows corrected QT interval more than 450ms in male, they will be excluded
from the study. This will filter out the subjects with the prolong QT interval caused by other
condition such as long QT syndrome.
After recruitment the researcher will be blinded to the treatment regimes and methadone
dosage. Recruited subjects then subsequently will be tested on urine drug test, electrolyte levels
and questioned about concomitant drug used. If urine drug test was positive or electrolyte
levels were abnormal or subjects were found to take medication that can alter Methadone level,
they will be excluded from study. However they can still be included in the study during the
next follow up.
Validated questionnaire will be used to grade the symptoms frequency according to the scale
(0 = never, 1 = seldom, 2 = frequent). Vitals signs, pupil size measurement, and ECG will be
taken using standardized equipment. Height, weight and other demographic data will be
taken from patient file in the clinic. Then blood samples will be taken for plasma level
measurement and genetic screening.
3. Results
3.1. Socio-demography
Forty nine subjects were enrolled into this study. All of our sample were Malay male, age
between 19 – 50 years old ( mean age 35.14 ± 6.66 ), weight ranged between 46kg to 73kg (mean
weight 61.41± 6.53) and with a mean height of 167.76±5.21 cm, ranged between 154cm to 181cm,
table 1. Mean value for heart rate, mean arterial pressure (MAP), respiratory rate, SPo2 and
pupil size were 85 beat per min, 89.13 mmHg, 9 breath per min, 98% saturation and 3mm pupil
size respectively (table 2).
Majority of patient had secondary education level (81.63%), 14.29% patients had education of
high school level, and 2.04% had education level of degree. Majority of them were single (51%)
while 34.7% were married and 7 or 14.3% of them were divorced.
Twenty patient or 40.8% was given less than 80mg oral methadone. Mean methadone dose
was 85.51mg ± 29.85sd while mean plasma level of methadone was 235.26 (±153.27). Mean
corrected QT interval was 442.49 (±20.42), table 3.
Variables (n= 49) Minimum Maximum Mean Std. Deviation
Height (cm) 154 181 167.76 5.206
Weight (kg) 46 73 61.41 6.529
Age(years) 19 50 35.14 6.658
Table 1. Descriptive statistics of height, weight and age of subjects
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Variables (n = 49) Minimum Maximum Mean Std. Deviation
spo2 (%) 95 100 98.00 1.646
mean arterial pressure (mmHg) 69.33 113.33 89.92 12.363
pulse rate (/min) 62 117 85.45 14.348
respiratory rate (breath/min) 6 16 9.18 1.976
pupil size (mm) 1 3 2.61 0.571
Table 2. Descriptive statistics of vital signs of the study subjects
Variables (n = 49) Minimum Maximum Mean Std. Deviation
methadone dose (mg) 30 160 85.51 29.85
plasma methadone
level (ng/ml) 26.90 708.50 235.26 153.27
QTc interval (ms) 409 500 442.49 20.42
Table 3. Descriptive Statistics of methadone dose, plasma methadone level and corrected QT interval
3.2. Methadone dose and its relationship with plasma methadone level
Methadone dosage in this study ranged between 30mg to 160mg with mean methadone dosage
of 85.51±29.85mg. Mean plasma methadone was 235.56 mg (minimum 26.90mg and maximum
of 708.50mg). Histogram for methadone dosage showed normal unimodal distribution curve
(figure 1) which signify normal paramateric distribution. Table 4 showed the association
between methadone dosage with its plasma level and other numerical variables. Using Simple
Linear Regression analysis, only plasma methadone level and corrected QT interval were
found to be statistically significant (p < 0.001 and CI didn’t cross 0). However R2 value
(coefficient of determination) was only ‘fair’ for plasma methadone level and QTc interval
(between 0.26 – 0.50). Therefore in summary, results from simple linear regression analysis
had shown that there were ‘fair’ linear relationships between methadone dose and plasma
level. For every increase in 1mg of methadone, there was an increase of 2.685 ng/ml of plasma
methadone level (p<0.001, b=2.685, 95% CI 1.436, 3.934) However only 28.5% of individual can
be explained by this regression model (R2 0.285). Scatter plot (figure 2) is showing the rela‐
tionship between plasma methadone and methadone dosage. Thus, relationship between
Methadone dosage and Plasma Methadone can be summarised with the equation:
Plasma Methadone (ng /ml)=  4.641 + 2.685(Methadone Dose in mg)
QTc interval also had a fairly significant linear regression with the methadone dose (p <0.001,
b = 0.287 (95%CI 0.147, 0.426), R2=0.267).
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Variable (n=49) Parameter vector, ba ( 95% C I) R
2(regression
coefficient) p value
Plasma methadone (mg) 2.685 (1.436 , 3.934) 0.285 0.001*
QTc (msec) 0.287 (0.147, 0.426) 0.267 0.001*
Pulse rate (/min) 0.17 ( 0.038,0.302 ) 0.125 0.103
Respiratory Rate (/min) 0.007 (-0.012 ,0.270) 0.013 0.439
MAP (mmHg) 0.06 (-0.153,0.09) 0.006 0.605
SpO2 (%) -0.006 ( - 0.022 , 0.01 ) 0.011 0.477
Pupil size (mm) -0.004 ( -0.010 , 0.001) 0.049 0.128
Height (m) 0.008 ( -0.044 , 0.059) 0.002 0.765
Weight (kg) 0.032 (- 0.088 , 0.930) 0.000 0.930
a = simple linear regression
* = statistically significance
All assumptions are met in statistically significant group
Table 4. Relationship between methadone dose with plasma methadone and other numerical variables
Figure 1. Histogram shows unimodal distribution of methadone dose
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Figure 2. Scatter plot shows correlation between plasma methadone and methadone dose
3.3. Comparison of ADR between high dose methadone (≥80mg) and low dose methadone
(<80mg)
Corrected QT interval was statistically significant (p = 0.025) when comparing between both
methadone groups using independent-t test. Mean QTc in low dose methadone group was
434.70 (13.79) while in high dose group was 447.86 (22.64), table 5. Using Simple Linear
regression, the association was fairly significant (p <0.001, b = 0.287 (95%CI 0.147, 0.426),
R2=0.267). Table 6 summarized the frequency and rate of symptoms attributed to different
groups of methadone maintenance therapy (MMT). Overall, side effects with statistically
significant p value (constipation, corrected QT interval, stomach upset, including nausea,
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vomiting, wind, diarrhoea, headache, lightheadedness and dizziness, chronic fatigue, sleepi‐
ness and exhaustion, drowsiness and sleepiness) showed strong positive association between
methadone dose and the frequency and severity of the side effects. In other words, with
increasing dose of methadone, there was high occurrence of more severe and frequent
symptoms. Between the two groups of methadone, constipation and stomach upset (including
nausea, vomiting, wind and diarrhea) were most significant symptoms (p = 0.001 and p =
0.003). Majority of subjects suffered from constipation in high dose methadone group (n = 27)
albeit with minimal frequency (seldom, n = 21 out of 29).
Constitutional  symptoms  such  as  stomach  upset  including  nausea,  vomiting,  wind  and
diarrhea were very common occurrence in patient taking methadone. Thirty seven of 49
patients  in  this  study  experienced  one  of  these  symptoms.  In  higher  group  of  metha‐
done, the situation is more pronounced (27 out of 29 patients) but less bothersome (sel‐
dom,  n  =  21).  Using  Chi  square  test/  Fischer  exact  test,  problems  with  erection  or
ejaculation, was the main hormonal side effect with a p value of 0.005. There were 16 pa‐
tients (seldom 11 and frequent 5) or more than 50% of patient from methadone ≥80mg is
having  problems  with  erection  or  orgasm.  This  was  in  contrast  with  low  dose  Metha‐
done group who has only 2 patients having infrequent symptoms (10%). Headache, light‐
headedness and dizziness were a common occurrence in both groups of  methadone (29
out of 49 subjects).  Although it was more common in high dose group (21 out of 29),  it
was mainly tolerable to subjects (seldom, n=21).  Chronic fatigue,  sleepiness and exhaus‐
tion were also common with a significant p<0.021.  In higher methadone group (>80mg),
there  was  at  least  one  episodes  of  fatigue,  sleepiness  and exhaustion  compared  to  low
dose (n = 4 in low dose methadone group while n=15 in high dose group). Patient who
suffered frequent symptoms also was higher in high dose group compared to low dose
group with n =5 and n= 4 respectively.  Nineteen out of 29 patients were suffering from
drowsiness  and  sleepiness,  with  15  of  them  were  having  infrequent  episodes  in  high
dose  methadone  group.  Only  6  patients  were  having  similar  symptoms  in  low  dose
methadone group, with all have them having mild symptoms.
Other potential life threatening symptoms such as shallow breathing, hypoventilation,
breathlessness and palpitation was not statistically significant when comparing between both
methadone groups. In that respect, both methadone groups had experienced almost similar
rate of symptoms.
Variables
Mean(SD)
Methadone< 80mg
(n= 20)
Mean (SD)
Methadone≥80mg
(n=29)
p value (95% CI)
QTC (ms) 434.70(13.79) 447.86(22.64) *0.025(1.73,24.60)
* statistically significant,
analysed by independent – t test
Table 5. Comparison of corrected QT interval between high dose methadone and low dose methadone
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Variables Methadone
<80mg
(n=20)
Methadone
≥80mg (n= 29) p value
Constipation
Never
Seldom
Frequent
10
10
0
2
21
6
*0.001a
Stomach upset, including nausea, vomiting, wind, diarrhoea
Never
Seldom
Frequent
9
11
0
2
22
5
*0.003a
Problems with erection and ejaculation
Never
Seldom
Frequent
18
2
0
13
11
5
*0.005a
Headache, lightheadedness, dizziness
Never
Seldom
Frequent
11
7
2
8
21
0
*0.017a
Chronic fatigue, sleepiness and exhaustion
Never
Seldom
Frequent
12
4
4
9
15
5
*0.021a
Drowsiness, sleepiness
Never
Seldom
Frequent
14
6
0
10
15
4
*0.029a
Breathlessness
Never
Seldom
Frequent
18
1
1
20
8
1
0.133a
Coughing
Never
Seldom
Frequent
18
1
1
18
10
1
0.052a
Shallow breathing
Never
Seldom
Frequent
19
1
0
20
8
1
0.083a
Palpitation
Never
Seldom
Frequent
19
0
1
20
6
3
0.062a
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Variables Methadone
<80mg
(n=20)
Methadone
≥80mg (n= 29) p value
Dry mouth
Never
Seldom
Frequent
8
1
1
25
4
0
0.124a
Hallucination
Never
Seldom
Frequent
20
0
0
26
3
0
0.138b
Euphoria, elated mood
Never
Seldom
Frequent
18
2
0
25
3
1
0.710a
Sad, depression, hopelessness
Never
Seldom
Frequent
17
3
0
29
0
0
0.062b
Weight gain
Never
Seldom
Frequent
12
7
1
10
15
4
0.187a
Rash
Never
Seldom
Frequent
20
0
0
22
6
1
0.060a
Galactorrhoea No data
Seizure, athetosis, abnormal movement No data
a = Chi Square test
b = Fischer exact test
* statistically significant, p<0.05
Table 6. Comparison of ADR between high dose methadone and low dose methadone (categorical variables)
3.4. Comparison of withdrawal or mixed side effects between low dose methadone (<80mg)
and high dose methadone (≥80mg)
Table 7 Illustrates a comparison of main withdrawal or mixed side effects between the two
groups of methadone. Using either Chi square test or Fischer exact test, itchiness was the most
significant (p =0.001) withdrawal side effect in this study. Eighteen out of 20 patients in low
dose methadone had at least 1 episodes of skin itchiness, although majority of them (n = 15)
was not frequent. High dose methadone group had only 8 mild skin itchiness cases and 1
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frequent case. It indicates that higher dose methadone group has less withdrawal side effect
including itchiness. Increase sweating had a second lowest p value at 0.005. Eight patients or
40% from lower methadone dose group have experienced increase sweating at some point of
time, but 7 of them experienced infrequent symptoms. Only 1 patient from higher methadone
group suffers from the same symptoms (3.5%).
Variables Methadone
<80mg (n=20)
Methadone
≥80mg (n=29) p value
Itchiness
Never
Seldom
Frequent
2
15
3
22
8
1
*0.001a
Increase sweating
Never
Seldom
Frequent
12
7
1
28
1
0
*0.005a
Insomnia, lack of sleep
Never
Seldom
Frequent
12
6
2
26
2
0
*0.033a
Flushing
Never
Seldom
Frequent
11
8
1
26
3
0
*0.019a
Poor weight gain, anorexia
Never
Seldom
Frequent
18
2
0
21
6
1
0.263a
Difficulty urination
Never
Seldom
Frequent
20
0
0
28
1
0
1.000b
Aggressive, agitation
Never
Seldom
Frequent
20
2
0
27
0
0
0.357b
Swelling of hand and feet No data
a = Chi Square test, b = Fisher Exact test
* statistically significant
Table 7. Comparison of main withdrawal side effects between high dose methadone and low dose methadone.
New Insights into Toxicity and Drug Testing232
Withdrawal patients also reported having flushing symptoms. Comparing the 2 groups of
methadone, there was a significant statistical significant (p = 0.019). Nine patients having
flushing symptoms in low dose group compared to 3 in high dose group.
Eight out of 20 patients were having insomnia or lack of sleep in low dose methadone group
(p = 0.033). However, majority (6 out of 8) were having only infrequent symptoms. In high
dose group, only 2 patients suffered from infrequent insomnia or lack of sleep (6.8%). Other
variables were not statistically significant.
4. Discussion
Some centre for methadone maintenance treatment (MMT) programs prescribe inadequate
daily methadone doses. Patients complain of withdrawal symptoms and continue illicit opioid
use, yet practitioners are reluctant to increase doses above certain arbitrary thresholds. Plasma
methadone levels (PMLs) may guide practitioners’ dosing decisions, especially for those
patients who have low PMLs despite higher methadone doses. To date, methadone dosing is
still an issue of debate and controversy among clinicians who are involved in methadone
maintenance programs. One meta analysis [35] which studied 24 articles suggest to have a goal
for methadone dosing in the range of 60 to 100 mg daily However newer research suggests
that doses ranging from 100 mg/d to more than 700 mg/d, with correspondingly higher PMLs,
may be optimal for many patients [36-39].There does not appear to be a maximum daily dose
limit when determining what is adequately “enough” methadone. In this study, there were 49
subjects taking daily methadone in the range of 30mg to 160mg. Mean methadone dosage was
85.51mg whereas methadone plasma levels ranged between 26.90 and 708.50 ng/ml with a
mean of 234.24 ng/ml. Results from this study showed there was a positive, fair and significant
correlation between methadone doses with its plasma level. (Pearson R = 0.36, Regression
coefficient, R2 =0.285, parameter vector b = 2.685, p = 0.001) and can be summarised into an
equation:
Plasma methadone (ng /ml) =  4.641 + 2.685 (methadone dose in mg)
Thus, according to the formula, every increase in 1mg of methadone, there was an increase of
2.685 ng/ml of plasma methadone level plus a constant (b=2.685, 95% CI 1.436, 3.934, p<0.001)
However only 28.5% of individual can be explained by this regression model (R2 0.285). Result
from our study is well replicated in other publication. Adelson et al. in 2007, had studied 151
MMT patient in Israel and found a significant correlation between methadone dosage and
plasma level (Pearson R = 0.36, P<0.005). The study also noted a stronger correlation in patient
who do not have illicit drugs [38]. Eap et al. reported on use of high methadone doses, as well
as methadone levels in the plasma; they evaluated 211 MMT patients (including 31 patients
who were undergoing dose reduction to stop treatment), all of whom were receiving the same
methadone dose for at least 5 days. [40]
The mean methadone dose in the 211 patients was 100 ± 58 mg/day, range 5-350 mg/days, and
their mean methadone level in plasma was 281 ± 169 ng/ml, range 16-976 ng/ml. They found
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a significant correlation between methadone levels in plasma and methadone doses expressed
as mg/kg body weight; the highest correlation was in patients with no co-medications
(benzodiazepines and antidepressants) or drug abuse, and with the active enantiomer R-
methadone (R = 0.65). The correlation with the racemic methadone solution was R = 0.50.
However, no scatter-plot was published. Results from this study and those highlighted here
shows that although the plasma methadone level was fairly correlated (R between 0.26 – 0.5),
true significant linear associations is impossible. This is because the plasma level depends on
the dose that the patient is actually taken, which can be subjected to cheating. It is well known
that some patients may abuse methadone. High blood levels of methadone may occur for
several reasons:
1. Up to 75% of the patients with high-methadone serum levels indeed were receiving high
methadone doses, above 70mg/day;
2. Some patients may obtain illicitly additional methadone or other illicit drugs outside the
clinic on any day;
3. Some patients, especially those who have take-home privileges, may not consume their
entire doses and may have sold some of the methadone.
There are several other factors that relate to inter-subject variability among patients’ serum
methadone level. Specific cytochrome P-450 gene polymorphisms which Eap et al. hypothe‐
sized might produce “slow metabolizers,” “rapid metabolizers,” and “ultra-rapid metabo‐
lizers”.  Chen  et  al.  in  2011,  studies  the  effect  CYP450  polymorphism  in  relation  to
withdrawal symptoms and side effects.  In this cross sectional study, the average metha‐
done  dose  was  55  mg/day  among 366  methadone  maintenance  patients  whose  average
steady-state plasma methadone concentrations were 193 and 142 ng/ml for R- and S-metha‐
done enantiomers. It found out a polymorphism of the CYP3A4 is associated with opioid
withdrawal  symptoms  (permutation,  p  <  0.0097),  especially  the  symptom  of  heart  rate,
which was assessed as an item within 11 items of the clinical opioid withdrawal scale total
score.CYP3A4 polymorphism also is associated with methadone side effects specifically the
sedation side effects.  The metabolism of methadone is  carried out through the CYP3A4,
CYP2B6,  CYP2C19  and  CYP2D6  isoenzymes  of  the  CYP  system  in  the  liver  [41,42].
Through the metabolic process, it produces an inactive metabolite 2-ethylidene-1, 5-dimeth‐
yl-3,  3-diphenylpyrrolidine (EDDP).  It  has been estimated that approximately 50% of all
clinical therapeutic drugs are metabolized by CYP3A4. The subfamily of CYP3A enzymes
is responsible for the other 30% of drug metabolism in adults, hence its activity and regula‐
tory mechanism may have an impact on methadone disposition and variability [43]. Apart
from polymorphism from CYP450 system, variation in acute α-glycoprotein (AAG) in plas‐
ma may play a significant role in its inter-individual variability. Methadone binds to plas‐
ma protein to a high degree of 86 percent, predominantly to acute α-glycoprotein (AAG)
[44]. AAG is an acute phase protein that exhibits significant variations in its plasma levels
according to the physiological and or pathological situation of the patient [45-47]. AAG lev‐
els are significantly increased in stress, leading to very low concentrations in the free frac‐
tion of methadone in cancer patients compared to healthy participants [48,49].
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Other factors that may contribute to variability include: age and sex. It has been suggested that
these factors may explain about 33 percent of the inter-individual variations in steady state
level [50]. From the study, females and increase in weight was found to have a positive linear
relationship. However, we could not replicate the findings in our study most probably due to
small sample size and “all male” subjects of our samples (for age, linear correlation, p = 0.77).
In summary this study has concurred with the current view (r =0.36) of fairly strong relation‐
ship between methadone dosage and plasma methadone in patient currently subscribed into
MMT. The correlation is higher when the patient has a complete abstinence from illicit drug.
Nevertheless only 28.5% (R2 0.285) of correlations can be explained by the correlation equation,
or in other words, the inter-variability between patient is huge. Factors such as polymorphism
of cytochrome P450 system especially CYP, variation in weight and gender, unpredictable
relationship between AAG and stress level and also patient factor is the main contributor for
this variation. Regardless of the route of administration, opioids can produce a wide spectrum
of unwanted side effects, especially during the early days of treatment when daily dose is being
stabilised. Some of these are distressing but generally not dangerous such as constipation,
sedation, itchiness, sweating, nausea and vomiting; whereas others are more serious and even
life-threatening like respiratory depression, severe hypotension and abnormal QT interval
(potentiates episodes of Torsade de Pointes (TdP). TdD is polymorphic ventricular tachycardia
(VT) characterized by a gradual change in the amplitude and twisting of the QRS complexes
around the isoelectric line. Often, Tdp is associated with a prolonged QT interval usually
terminates spontaneously but frequently recurs and may degenerate into ventricular fibrilla‐
tion. The ventricular rate can range from 150 beats per minute (bpm) to 250 bpm. The QT
interval requires to be increased markedly (600 msec or greater). Therefore, a prolonged QT
interval signifies a higher risk of arrhythmias especially TdP, which can deteriorates into
sudden cardiac failure and sudden death. In vitro studies of levomethadyl, methadone, and
buprenorphine have each demonstrated considerable blockade of the human ether-a-go-go-
related–gene (hERG) channel activity, a property that is strongly associated with prolongation
of the QT interval and the induction of torsade de pointes ventricular tachycardia (TdP) [51].
Mean and SD for corrected QT interval was 434.70(13.79) ms for low dose methadone group
and 447.86(22.64) for high dose methadone group. Independent t- test showed statistically
significant different between these two groups (t =2.316, mean difference = 13.16, p value =
0.025, CI = 1.73, 24.6) (table 3).
In addition, simple linear regression showed there is fair association between methadone dose
and corrected QT (R=0.404, b = 0.287, CI = 0.147, 0.426, R2 = 0.267, p = 0.001). Although this result
proved there is an association between methadone dose and QTc, only 26.7% of the patient
can be predicted by the result (R2 = 0.267) (table 2).
Results from this study are in line with dozens other findings in proving the association
between methadone dose and prolongation of QTc. [52-55]. As with most QT interval pro‐
longing drugs, the effects of methadone on cardiac repolarization are dose dependent, as
evident in case reports as well as cross-sectional and prospective studies. Methadone dosages
exceeding 100 mg/d have frequently been noted in published cases of torsade de pointes, and
some case reports [56-58] highlight QTc interval normalization after methadone discontinua‐
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tion or dose reduction. Furthermore, many studies, including those of oral and intravenous
methadone, demonstrate a positive correlation between doses and delayed cardiac repolari‐
zation [59-63] among both addiction treatment and pain management cohorts. In Peles and
colleagues’ study [61], the correlation achieved statistical signiﬁcance in the subset of patients
abusing cocaine, which is consistent with a synergistic effect of methadone and cocaine on
hERG channel blockade. In Fanoe and colleagues’ study, the QTc interval increased by 10 ms
for every 50-mg increase in methadone dose, which corresponded to a higher risk for syncope
(odds ratio, 1.2 [CI, 1.1 to 1.4]). Cruciani et al. found the correlation between methadone doses
with QTc in “all male” subjects similar to this study. With regard to serum levels, Martell and
colleagues prospectively demonstrated that the increase in QTc interval from baseline to 12
months after methadone initiation correlated with both trough and peak serum concentrations.
Wedam and colleagues observed similar relationships with the methadone derivative
levacetylmethadol. This creates a safety– efficacy paradox, because higher doses of methadone
may reduce illicit opioid use (or diminish chronic pain) yet place patients at greater arrhythmia
risk. It is important for clinicians to recognize that sudden cardiac death associated with
methadone has been described at dosages as low as 29 mg/day, which suggests that arrhythmia
can occur across a wide therapeutic range that includes dosages commonly used in both
chronic pain and addiction treatment. This in turn suggests that methadone dosage is just one
consideration with regard to limiting arrhythmia risk.
In view of the overwhelming evidence which associate methadone dose with prolonged QTc
and subsequent Torsades de Pointes, a clinical guidelines in QTc interval screening in
methadone therapy was proposed by Krantz et al. (2009) [64].
Respiratory depression, the hallmark of serious opioid overdose, is only seen in about 50% of
patients with CNS depression and should not to be confused with [65]. It is also synonymous
with drowsiness and lethargy which may confuse the observer. Methadone can reduces or
eliminates the normal drive to recommence respiration or increase the rate once it diminished
in the body. Overdose-induced adult respiratory distress syndrome (ARDS) has also been
described for methadone toxicity [66].
Methadone overdose can follow an unpredictable course in non-tolerant patients who are at
risk of death. When methadone is consumed, the effect on the breathing pattern depends on
the plasma concentration of the drug. At low concentrations there is a decrease in tidal volume
(normal volume of air breathed in and out), but no change in respiratory rate; at higher
concentrations both tidal volume and rate are depressed [67]. Preclinical studies indicate that
at very high concentrations, there may be some additional disruption to respiration as a result
of NMDA (N-methyl-D-Aspartate) antagonism [68] and possible serotonergic (re-uptake
inhibition) and catecholaminergic activity [69].
Generally, opioid activates the mesolimbic reward system in the midbrain. Subsequently, the
system generates signals in the ventral tegmental area. As a result, dopamine neurotransmitter
is released from the nucleus accumbens result in feelings of pleasure. Other areas of the brain
create a lasting memory that associates these good feelings with the circumstances and
environment in which they occur. These memories, called conditioned associations, often lead
to the craving for drugs. Beside relieving craving and withdrawal, methadone on the other
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hand, through G-protein–coupled mechanisms also directly affect cation channel function in
the postsynaptic membrane. Methadone as an agonist at both mu and delta receptors acts to
increase potassium channel opening (reducing production of cAMP through inhibition of
adenylate cyclase activity) and decrease the opening of voltage-operated calcium channels
(inhibiting inward Ca 2+ currents). Consequent reduction in neuronal membrane excitability
(depolarizing effect) exerts an inhibitory effect upon respiratory systems to diminish sensitiv‐
ity to changes in O2 and CO2 outside normal concentration ranges [70]. Mu and delta receptor
activity contribute in an additive way to respiratory depression. Several studies have investi‐
gated the control of respiration during chronic dosing (MMT) with the drug. Usually, while
PaO2 in blood is normal, dopamine is released inhibiting chemoreceptors in the carotid and
aortic bodies. Hypoxia reduces the release of this dopamine and in doing so releases chemo‐
receptors, which stimulate the respiratory centre. Santiago et al. [72] found at the start (< 2
months) of MMT, ventilation was reduced and arterial blood gas altered, along with decreased
sensitivity of CNS chemoreceptors to both CO2 and hypoxia. However, after more than 8
months in MMT these indices had returned to normal except for the persistent reduction in
sensitivity of the CNS receptors to hypoxia.
Durstellar et al. in 2010, had compared multiple symptoms of methadone to heroin in opioid
dependence [72]. Breathing difficulties were encountered more in methadone group at 25.4%
out of 63 patients compared to heroin group (11.1% out of 54 patients; p < 0.05).
Our samples showed similar rate in both methadone group; breathlessness (11 patient out of
49 or 22.45%, where 9 in high dose group, 2 in low dose group), shallow breathing (10 patients
out of 49 or 20.41%, where 9 were in high dose group and coughing (13 out of 49 patients or
26.5%). However when comparing between low dose methadone and high dose methadone
groups, none were statistically significant.
Looking at the respiratory symptoms pattern, up to 20-25% of the patient had experienced
some degree of respiratory symptoms attributable to methadone or indeed other opioids.
However, life threatening respiratory compromise remains rare as evidence from mortality
review worldwide [73-75]. Like early research by Santiago et al. which has been stated above,
Marks and Goldring [76] found hypercapnia uniformly developed in the early phases of
methadone treatment persisting for up to 8 months and which was consistently associated
with alteration in the central control of ventilation.
Although results from this study were comparable with previous study, more refined research
with better methodology especially in detecting respiratory depression in induction phase
(first 6 month) is warranted to study the dose-dependent respiratory depression.
5. Conclusion
In summary this study has concurred with the current view (r =0.36) of fairly strong relation‐
ship between methadone dosage and plasma methadone in patient currently subscribed into
MMT. The correlation is higher when the patient has a complete abstinence from illicit drug.
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Nevertheless only 28.5% (R2 0.285) of correlations can be explained by the correlation equation,
or in other words, the inter-variability between patient is huge. Factors such as polymorphism
of cytochrome P450 system especially CYP, variation in weight and gender, unpredictable
relationship between AAG and stress level and also patient factor is the main contributor for
this variation
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